The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I trial of docetaxel/prednisone plus fractionated dose radiolabeled anti-prostate-specific membrane antigen (PSMA) monoclonal antibody 177lu-J591 in patients with metastatic, castration-resistant prostate cancer (mCRPC).
Scott T. Tagawa
Consultant or Advisory Role - ATLAB Pharma (U)
Honoraria - Sanofi
Research Funding - Sanofi
Young E. Whang
No relevant relationships to disclose
Gurveen Kaur
No relevant relationships to disclose
Shankar Vallabhajosula
No relevant relationships to disclose
Paul J. Christos
No relevant relationships to disclose
Anastasia Nikolopoulou
No relevant relationships to disclose
Yuliya Jhanwar
No relevant relationships to disclose
Arif Sheikh
No relevant relationships to disclose
Adam Ireland
No relevant relationships to disclose
Carmen Garcias-Espana
No relevant relationships to disclose
Stanley J. Goldsmith
No relevant relationships to disclose
Himisha Beltran
Research Funding - Sanofi
Neil Harrison Bander
Consultant or Advisory Role - BZL Biologics
David M. Nanus
No relevant relationships to disclose